2023 has been a tumultuous year for global markets, but despite these challenges, our team has consistently strived for excellence. We have faced these challenges with resilience and determination, never backing down nor giving up. Thanks to our team’s relentless effort and all of our partner's support, we continue to stand strong in an ever-changing market and take a leading position in the rapidly evolving industry.
Over the past year, we have continuously unleashed the power of innovation, receiving seven IND approvals. Additionally, Orelabrutinib has become the first and only BTK inhibitor approved for the treatment of relapsed or refractory Marginal Zone Lymphoma (r/r MZL) in China, an indication which has been included in the updated 2023 National Reimbursement Drug List (NRDL).
In our mission to provide patients with the best innovative medicines in the world, we have never ceased exploring more possibilities and have continuously forged ahead on the road to improving public health. The phase II study results of our novel TYK2 Inhibitor, ICP-332, met the primary endpoints in patients with moderate-to-severe atomic dermatitis. Furthermore, we have entered into a strategic collaboration with ArriVent to evaluate the efficacy and safety of ICP-189 in combination with furmonertinib in patients with non-small cell lung cancer.
Over the past year, we have continued to accelerate our pace of development. Across the globe, we have been striving for excellence. This year, we have achieved significant milestones: the removal of the “B” from our stock code of the Hong Kong Stock Exchange marking us as a full-fledged biopharmaceutical company, the approval and launch of tafasitamab in the Greater Bay Area, the acceleration of commercialization and globalization, as well as the further advancement of our innovation drug base in Guangzhou and Beijing. From 1.0 to 2.0, from biotech to biopharma, we will continue our hard work to achieve more milestones.
As the new year approaches, we remain steadfast in our pursuit of excellence, ready to embrace an even more fruitful year in 2024.
As we look ahead to 2024, it's essential that we uphold our entrepreneurial spirit and turn our dreams into reality through outstanding performance.
We must maintain the spirit of continuous innovation, aligning with international standards to innovate based on our leading technology platforms, with the goal of launching five to six innovative drugs onto the market within three to five years to benefit patients around the world.
We will continue to uplift our commercialization capabilities, enhance our global presence, and upgrade our entire industry chain, so as to develop into a world-leading biopharma company.
Finally, I sincerely wish you all great successes in the Year of the Dragon!